ZEON CORPORATION
1-6-2 Marunouchi, Chiyoda-ku, Tokyo 100-8246 Japan

November 12, 2025

Zeon Corporation

Zeon signs business transfer agreement with Kaneka Corporation for the medical products business

Zeon Corporation (Zeon; head office: Chiyoda-ku, Tokyo; President and CEO: Tetsuya Toyoshima) has announced that it reached an agreement with Kaneka Corporation (Kaneka; head office: Minato-ku, Tokyo; President: Kazuhiko Fujii) and, on November 12, 2025, entered into an agreement to transfer the medical products business in the digestive and circulatory systems fields currently operated by Zeon Group companies Zeon Medical Inc. (Zeon Medical) and River Xemex Ltd. (River Xemex).

Zeon established Zeon Medical in 1989 to manage the sales of auxiliary artificial heart pumps that Zeon had been developing since 1979. Since its founding, Zeon Medical has leveraged Zeon's R&D expertise to advance proprietary material processing technologies and to provide treatment and diagnostic devices for the digestive and circulatory systems fields, thereby helping to reduce the physical burden on patients. However, as clinical needs become increasingly diverse, it is now essential to enhance the performance of existing devices while developing and supplying a broader range of products. These factors have presented challenges to further business growth in recent years.

Zeon has carefully reviewed the strategic position of its medical products business in light of Group-wide strategies, potential synergies, and an assessment of the most suitable owner. As a result, Zeon has decided that transferring the business to Kaneka, which possesses advanced technologies, a strong track record, and a broad customer base in the medical products field, is in the best interests of the business's customers, patients, and stakeholders.

We remain committed to pursuing initiatives in healthcare and life sciences, one of the four growth areas outlined in our STAGE30 medium-term management plan. Centered on high-performance materials, Zeon will continue focusing on both current and next-generation growth drivers in this area. Furthermore, by promoting portfolio restructuring through "Selection and Concentration" to improve capital efficiency, we will continue contributing to a "Sustainable Earth" and a "Safe and Comfortable Life for People" through the provision of original technologies, products, and services.

Overview of the counterparty to the agreement

Company name: Kaneka Corporation

Address: ARK Mori Building, 1-12-32 Akasaka, Minato-ku, Tokyo

Representative: Kazuhiko Fujii, President

Paid-in capital: JPY 33.046 billion

Established: 1949

Overview of Group companies subject to business transfer

Company name: Zeon Medical Inc.

Address: Shin Marunouchi Center Building, 1-6-2 Marunouchi, Chiyoda-ku, Tokyo

Representative: Junichi Watanabe, President

Paid-in capital: JPY 452 million

Major shareholder and ownership ratio: Zeon Corporation (100%)

Established: 1989

Company name: River Xemex Ltd.

Address: 2-11-17 Osachigosho, Okaya City, Nagano Prefecture

Representative: Junichi Watanabe, President

Paid-in capital: JPY 30 million

Major shareholder and ownership ratio: Zeon Medical Inc. (100%)

Established: 1999

For more information, contact:

Department of Corporate Communications, Corporate Sustainability Division, Zeon Corporation

Phone: +81-3-3216-2747 Contact form